Company Overview
Metagenomi Therapeutics, Inc. operates as an in vivo genome editing company focused on developing curative genetic medicines for patients within the United States. The company's primary asset, the lead development program MGX-001, is engineered to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. This biotechnology entity functions within the broader Healthcare sector, specifically targeting the specialized industry of Biotechnology where high-risk, high-reward R&D drives innovation. With a market capitalization of $49.66M, an annual revenue of $25.21M, and a workforce of 119 employees, the company represents a small-cap asset in the genetic medicine space. These valuation and revenue figures indicate that the company is in a growth phase typical of early-stage biotechs, where cash reserves are critical for sustaining R&D operations before reaching profitability milestones.
Financial Health
The company reported revenue of $25.21M over the trailing twelve months, yet this revenue generated a net income loss of $87,868,000, revealing a cost structure where expenses significantly outweigh income. EBITDA for the period was negative at $90,696,000, further highlighting the substantial operational burn required to advance the company's genetic editing pipeline. Free cash flow stands at $53,307,124 in the negative, indicating that the company is consuming cash to fund its development activities and lacks immediate financial flexibility to pay down debt or return capital. The gross margin is listed at -274.6%, an anomaly in traditional reporting that reflects the heavy capitalization of R&D costs against minimal sales, while the operating margin of -623.0% and profit margin of 0.0% underscore the deep losses inherent in the pre-commercialization biotechnology lifecycle. Despite these losses, the company holds $160.80M in cash against $40.66M in debt, resulting in a debt-to-equity ratio of 25.64, which suggests a highly leveraged balance sheet relative to equity but one supported by a significant cash buffer. The current ratio is 7.22, indicating that the company possesses ample short-term liquid assets to cover its short-term liabilities without immediate distress. Return on Equity is -44.7% and Return on Assets is -22.0%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a standard characteristic for firms in the R&D-intensive biotechnology sector.
Valuation Assessment
The P/E Ratio (TTM) is not available due to negative earnings, while the Forward P/E is -0.79, a negative figure that implies earnings are expected to remain negative in the immediate future rather than indicating a discount to earnings. The price-to-book ratio is 0.31, suggesting that the market values the company at a fraction of its book value, often seen in speculative biotech stocks where future pipeline value outweighs current assets. The price-to-sales ratio is 1.97, and the EV/EBITDA is 0.78, providing alternative valuation lenses that show the company is trading at less than two times its sales, a metric often used when earnings are negative to assess revenue quality relative to valuation. The stock's 52-week high is $3.95 and its 52-week low is $1.23; without a specific current price provided in the data, the valuation context relies on these bounds to show the volatility range within which the stock has traded. The Beta is 0.47, indicating that the stock's price volatility is significantly lower than the broader market, suggesting it is less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Revenue growth year-over-year is -59.3%, while earnings growth is not available, indicating that the company is currently contracting in terms of top-line sales rather than expanding. The absence of positive earnings growth relative to revenue contraction suggests that the company is still in a phase where sales are insufficient to cover the fixed costs of research and development. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available resources into its development programs rather than distributing income to shareholders. Consequently, the overall growth and income profile for Metagenomi Therapeutics, Inc. is characterized by negative revenue growth and a complete lack of current income generation, relying entirely on the potential future value of its pipeline to justify its current market capitalization.